{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:29:20Z","timestamp":1777861760137,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"King\u2019s-China Scholarship Council PhD Scholarship Programme."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug-induced liver injury (DILI) remains a significant barrier to the safe and efficient use of antimalarial medicines. Many promising compounds fail in late-stage development or post-marketing owing to unforeseen toxicity, particularly DILI. Incorporating a predictive hepatotoxicity assessment is therefore critical to reduce clinical risk and development costs. The Medicines for Malaria Venture (MMV) Global Health Priority Box (GHPB) provides a library of compounds with demonstrated or potential antimalarial activity, yet their hepatotoxicity risk remains poorly defined. Our early work developed and validated a nanoscaffold-based three-dimensional (3D) liver spheroid platform. Here, we apply this validated model for the first time to assess the hepatotoxicity of clinically used and candidate antimalarial GHPB compounds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Our validated nanoscaffold-based 3D liver spheroid platform was used to evaluate the hepatotoxicity of approved antimalarial drugs of known liver toxicity (quinine, primaquine, amodiaquine, sulfadoxine\/pyrimethamine, and artemisinin) and six GHPB candidate compounds. Half maximal inhibitory concentration (IC\n                      <jats:sub>50<\/jats:sub>\n                      )-derived data from the approved antimalarial drugs were used to generate a reference framework on the basis of established DILI classifications, which was then applied to categorize the GHPB candidate compounds relative to hepatotoxic risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our nanoscaffold-based 3D liver spheroid platform accurately reproduced the known DILI rankings of the approved antimalarials, confirming its predictive validity. Using these referenced IC\n                      <jats:sub>50<\/jats:sub>\n                      -derived profiles, candidate compounds from the GHPB were classified into distinct hepatotoxicity categories, ranging from low: MMV1167451 (compound 01) and MMV020192 (compound 02), moderate: MMV1797658 (compound 03) and MMV1435700 (compound 04), to high: MMV006344 (compound 05) and MMV006931 (compound 06) risk, demonstrating the model\u2019s capacity to support early-stage animal-free antimalarial hepatotoxicity screening.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates the translational application of a validated nanoscaffold-based 3D human liver spheroid model for antimalarial drug in vitro hepatotoxicity assessment. By establishing a reference framework from clinically approved antimalarials and applying it to candidate compounds from the MMV GHPB, our platform enabled early classification of hepatotoxicity risk using a human-relevant, non-animal method. The findings support the integration of advanced 3D in vitro systems into antimalarial drug discovery pipelines to improve safety prediction, reduce reliance on animal testing, and accelerate the development of safer, more effective antimalarial therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13071-026-07324-1","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:04:20Z","timestamp":1774260260000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanoscaffold-based 3D human liver spheroids for predictive hepatotoxicity screening of antimalarial compounds from the global health priority box"],"prefix":"10.1186","volume":"19","author":[{"given":"Lina","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Driton","family":"Vllasaliu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Ayoola","family":"Mabayoje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Aspinall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahijja Tolulope","family":"Raimi-Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"7324_CR1","unstructured":"World malaria report 2024: addressing inequity in the global malaria response. Geneva:World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO."},{"key":"7324_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cell.2016.07.055","volume":"167","author":"AF Cowman","year":"2016","unstructured":"Cowman AF, Healer J, Marapana D, Marsh K. Malaria: biology and disease. Cell. 2016;167:610\u201324.","journal-title":"Cell"},{"key":"7324_CR3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jinf.2016.02.001","volume":"72","author":"DG Lalloo","year":"2016","unstructured":"Lalloo DG, Shingadia D, Bell DJ, Beeching NJ, Whitty CJM, Chiodini PL. UK malaria treatment guidelines 2016. J Infect. 2016;72:635\u201349.","journal-title":"J Infect"},{"key":"7324_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000109767","volume":"53","author":"HO AlKadi","year":"2007","unstructured":"AlKadi HO. Antimalarial drug toxicity: a review. Chemotherapy. 2007;53:385\u201391.","journal-title":"Chemotherapy"},{"key":"7324_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/00365521.1974.12096796","volume":"9","author":"M T\u00f6nder","year":"1974","unstructured":"T\u00f6nder M, Nord\u00f6y A, Elgjo K. Sulfonamide-induced chronic liver disease. Scand J Gastroenterol. 1974;9:93\u20136.","journal-title":"Scand J Gastroenterol"},{"key":"7324_CR6","unstructured":"WHO Scientific Group on the Chemotherapy of Malaria\u00a0&\u00a0World Health Organization. Practical chemotherapy of malaria : report of a WHO scientific group [meeting held in Geneva from 5 to 12 June 1989].\u00a0World Health Organization.\u00a0World Health Organization; 1990.\u00a0https:\/\/iris.who.int\/handle\/10665\/39778. Accessed 18th Sep 2025."},{"key":"7324_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-2-6","volume":"2","author":"AM Croft","year":"2002","unstructured":"Croft AM, Herxheimer A. Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement? BMC Public Health. 2002;2:6.","journal-title":"BMC Public Health"},{"key":"7324_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0105-0","volume":"5","author":"RJ Andrade","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5:1\u201322.","journal-title":"Nat Rev Dis Primers"},{"key":"7324_CR9","unstructured":"GOV.UK. UK improves access to life-saving malaria drugs. GOV.UK. https:\/\/www.gov.uk\/government\/news\/uk-improves-access-to-life-saving-malaria-drugs. Accessed 9 Oct 2024."},{"key":"7324_CR10","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1021\/acsinfecdis.4c00700","volume":"10","author":"A Adam","year":"2024","unstructured":"Adam A, Besson D, Bryant R, Rees S, Willis PA, Burrows JN, et al. Global health priority box\u2500proactive pandemic preparedness. ACS Infect Dis. 2024;10:4030\u20139.","journal-title":"ACS Infect Dis"},{"key":"7324_CR11","unstructured":"Medicines for Malaria Venture: Developing antimalarials to save lives. https:\/\/www.mmv.org\/(2025). Accessed 9 Oct 2024."},{"key":"7324_CR12","unstructured":"U.S. FDA. New Drug Development and Review Process. U.S. FDA. 2023; https:\/\/www.fda.gov\/drugs\/cder-small-business-industry-assistance-sbia\/new-drug-development-and-review-process. Accessed 28 Aug 2024."},{"key":"7324_CR13","unstructured":"Temple R. Guidance for Industry. Drug Saf. 2009;28."},{"key":"7324_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1006\/rtph.2000.1399","volume":"32","author":"H Olson","year":"2000","unstructured":"Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol. 2000;32:56\u201367.","journal-title":"Regul Toxicol Pharmacol"},{"key":"7324_CR15","unstructured":"Sen. Paul R. FDA Modernization Act 2.0. 2022. https:\/\/www.congress.gov\/bill\/117th-congress\/senate-bill\/5002. Accessed 28 Aug 2024."},{"key":"7324_CR16","unstructured":"Rep. Carter EL. FDA Modernization Act 3.0. 2024. https:\/\/www.congress.gov\/bill\/118th-congress\/house-bill\/7248. Accessed 28 Aug 2024."},{"key":"7324_CR17","first-page":"1","volume":"11","author":"V Chunduri","year":"2022","unstructured":"Chunduri V, Maddi S. Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: a comprehensive review. ADMET DMPK. 2022;11:1\u201332.","journal-title":"ADMET DMPK"},{"key":"7324_CR18","first-page":"910","volume":"14","author":"M Kapa\u0142czy\u0144ska","year":"2018","unstructured":"Kapa\u0142czy\u0144ska M, Kolenda T, Przyby\u0142a W, Zaj\u0105czkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures\u2014a comparison of different types of cancer cell cultures. Arch Med Sci AMS. 2018;14:910\u20139.","journal-title":"Arch Med Sci AMS"},{"key":"7324_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45144-w","volume":"13","author":"ZN Abbas","year":"2023","unstructured":"Abbas ZN, Al-Saffar AZ, Jasim SM, Sulaiman GM. Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations. Sci Rep. 2023;13:18380.","journal-title":"Sci Rep"},{"key":"7324_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/toxsci\/kfx289","volume":"162","author":"CC Bell","year":"2018","unstructured":"Bell CC, Dankers ACA, Lauschke VM, Sison-Young R, Jenkins R, Rowe C, et al. Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study. Toxicol Sci. 2018;162:655\u201366.","journal-title":"Toxicol Sci"},{"key":"7324_CR21","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.3748\/wjg.15.2817","volume":"15","author":"G Tarantino","year":"2009","unstructured":"Tarantino G, Di Minno MND, Capone D. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol. 2009;15:2817\u201333.","journal-title":"World J Gastroenterol"},{"key":"7324_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.diff.2019.02.004","volume":"106","author":"MT Donato","year":"2019","unstructured":"Donato MT, Tolosa L. Stem-cell derived hepatocyte-like cells for the assessment of drug-induced liver injury. Differentiation. 2019;106:15\u201322.","journal-title":"Differentiation"},{"key":"7324_CR23","doi-asserted-by":"publisher","first-page":"12046","DOI":"10.3390\/ijms241512046","volume":"24","author":"O Urz\u00ec","year":"2023","unstructured":"Urz\u00ec O, Gasparro R, Costanzo E, De Luca A, Giavaresi G, Fontana S, et al. Three-dimensional cell cultures: the bridge between in vitro and in vivo models. Int J Mol Sci. 2023;24:12046.","journal-title":"Int J Mol Sci"},{"key":"7324_CR24","doi-asserted-by":"publisher","first-page":"25610","DOI":"10.1021\/acsami.3c17384","volume":"16","author":"L Wu","year":"2024","unstructured":"Wu L, Vllasaliu D, Cui Q, Raimi-Abraham BT. In situ self-assembling liver spheroids with synthetic nanoscaffolds for preclinical drug screening applications. ACS Appl Mater Interfaces. 2024;16:25610\u201321.","journal-title":"ACS Appl Mater Interfaces"},{"key":"7324_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2020.611913","volume":"2","author":"CR Cox","year":"2020","unstructured":"Cox CR, Lynch S, Goldring C, Sharma P. Current perspective: 3D spheroid models utilizing human-based cells for investigating metabolism-dependent drug-induced liver injury. Front Med Technol. 2020;2:611913.","journal-title":"Front Med Technol"},{"key":"7324_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120983","volume":"275","author":"LP Ferreira","year":"2021","unstructured":"Ferreira LP, Gaspar VM, Mendes L, Duarte IF, Mano JF. Organotypic 3D decellularized matrix tumor spheroids for high-throughput drug screening. Biomaterials. 2021;275:120983.","journal-title":"Biomaterials"},{"key":"7324_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.actbio.2021.10.031","volume":"138","author":"S Hong","year":"2022","unstructured":"Hong S, Song JM. 3D bioprinted drug-resistant breast cancer spheroids for quantitative in situ evaluation of drug resistance. Acta Biomater. 2022;138:228\u201339.","journal-title":"Acta Biomater"},{"key":"7324_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120529","volume":"269","author":"G Lee","year":"2021","unstructured":"Lee G, Kim H, Park JY, Kim G, Han J, Chung S, et al. Generation of uniform liver spheroids from human pluripotent stem cells for imaging-based drug toxicity analysis. Biomaterials. 2021;269:120529.","journal-title":"Biomaterials"},{"key":"7324_CR29","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1111\/febs.15776","volume":"288","author":"NK Karamanos","year":"2021","unstructured":"Karamanos NK, Theocharis AD, Piperigkou Z, Manou D, Passi A, Skandalis SS, et al. A guide to the composition and functions of the extracellular matrix. FEBS J. 2021;288:6850\u2013912.","journal-title":"FEBS J"},{"key":"7324_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2021.105876","volume":"163","author":"L Belfiore","year":"2021","unstructured":"Belfiore L, Aghaei B, Law AMK, Dobrowolski JC, Raftery LJ, Tjandra AD, et al. Generation and analysis of 3D cell culture models for drug discovery. Eur J Pharm Sci. 2021;163:105876.","journal-title":"Eur J Pharm Sci"},{"key":"7324_CR31","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1039\/C6TX00101G","volume":"5","author":"H Gaskell","year":"2016","unstructured":"Gaskell H, Sharma P, Colley HE, Murdoch C, Williams DP, Webb SD. Characterization of a functional C3A liver spheroid model. Toxicol Res. 2016;5:1053\u201365.","journal-title":"Toxicol Res"},{"key":"7324_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130348","volume":"10","author":"X Gong","year":"2015","unstructured":"Gong X, Lin C, Cheng J, Su J, Zhao H, Liu T, et al. Generation of multicellular tumor spheroids with microwell-based agarose scaffolds for drug testing. PLoS One. 2015;10:e0130348.","journal-title":"PLoS One"},{"key":"7324_CR33","doi-asserted-by":"publisher","first-page":"2200169","DOI":"10.1002\/adtp.202200169","volume":"6","author":"A Sae-be","year":"2023","unstructured":"Sae-be A, Wiwatpanit T, Varatthan T, Namporn T, Laungkulldej S, Thiabma R, et al. Comparative study between the 3D-liver spheroid models developed from HepG2 and immortalized hepatocyte-like cells with primary hepatic stellate coculture for drug metabolism analysis and anticancer drug screening. Adv Ther. 2023;6:2200169.","journal-title":"Adv Ther"},{"key":"7324_CR34","unstructured":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/. Accessed 26 Jan 2024."},{"key":"7324_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231163410","volume":"16","author":"T Hosack","year":"2023","unstructured":"Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. Ther Adv Gastroenterol. 2023;16:17562848231163410.","journal-title":"Ther Adv Gastroenterol"},{"key":"7324_CR36","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1146\/annurev.pharmtox.45.120403.100058","volume":"45","author":"BK Park","year":"2005","unstructured":"Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol. 2005;45:177\u2013202.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"7324_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/toxsci\/kfp088","volume":"110","author":"JS MacDonald","year":"2009","unstructured":"MacDonald JS, Robertson RT. Toxicity testing in the 21st century: a view from the pharmaceutical industry. Toxicol Sci. 2009;110:40\u20136.","journal-title":"Toxicol Sci"},{"key":"7324_CR38","first-page":"147","volume":"16","author":"V Ahmad","year":"2021","unstructured":"Ahmad V. Prospective of extracellular matrix and drug correlations in disease management. Asian J Pharm Sci. 2021;16:147\u201360.","journal-title":"Asian J Pharm Sci"},{"key":"7324_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02484-1","volume":"41","author":"A Jurj","year":"2022","unstructured":"Jurj A, Ionescu C, Berindan-Neagoe I, Braicu C. The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes? J Exp Clin Cancer Res. 2022;41:276.","journal-title":"J Exp Clin Cancer Res"},{"key":"7324_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/MCG.0b013e31818a3854","volume":"43","author":"LJ Chun","year":"2009","unstructured":"Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol. 2009;43:342.","journal-title":"J Clin Gastroenterol"},{"key":"7324_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2019.104669","volume":"62","author":"Y Tang","year":"2020","unstructured":"Tang Y, Wu Q, Beland FA, Chen S, Fang J-L. Apoptosis contributes to the cytotoxicity induced by amodiaquine and its major metabolite N-desethylamodiaquine in hepatic cells. Toxicol In Vitro. 2020;62:104669.","journal-title":"Toxicol In Vitro"},{"key":"7324_CR42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40262-021-01001-5","volume":"60","author":"Y Song","year":"2021","unstructured":"Song Y, Li C, Liu G, Liu R, Chen Y, Li W, et al. Drug-metabolizing cytochrome P450 enzymes have multifarious influences on treatment outcomes. Clin Pharmacokinet. 2021;60:585\u2013601.","journal-title":"Clin Pharmacokinet"},{"key":"7324_CR43","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1124\/dmd.31.6.748","volume":"31","author":"D Projean","year":"2003","unstructured":"Projean D, Baune B, Farinotti R, Flinois J-P, Beaune P, Taburet A-M, et al. In vitro metabolism of chloroquine: identification of Cyp2c8, Cyp3a4, and Cyp2d6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003;31:748\u201354.","journal-title":"Drug Metab Dispos"},{"key":"7324_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2165\/00003088-200140050-00003","volume":"40","author":"PT Giao","year":"2001","unstructured":"Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40:343\u201373.","journal-title":"Clin Pharmacokinet"},{"key":"7324_CR45","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0006-2952(98)00217-2","volume":"56","author":"M Vezmar","year":"1998","unstructured":"Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem Pharmacol. 1998;56:733\u201342.","journal-title":"Biochem Pharmacol"},{"key":"7324_CR46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/17425255.2022.2049235","volume":"18","author":"L Pernaute-Lau","year":"2022","unstructured":"Pernaute-Lau L, Camara M, de N\u00f3brega Sousa T, Morris U, Ferreira MU, Gil JP. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria. Expert Opin Drug Metab Toxicol. 2022;18:39\u201359.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"7324_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2024.153829","volume":"505","author":"B Sun","year":"2024","unstructured":"Sun B, Liang Z, Wang Y, Yu Y, Zhou X, Geng X, et al. A 3D spheroid model of quadruple cell co-culture with improved liver functions for hepatotoxicity prediction. Toxicology. 2024;505:153829.","journal-title":"Toxicology"},{"key":"7324_CR48","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00228-002-0512-z","volume":"58","author":"TE Bapiro","year":"2002","unstructured":"Bapiro TE, Andersson TB, Otter C, Hasler JA, Masimirembwa CM. Cytochrome P450 1A1\/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002;58:537\u201342.","journal-title":"Eur J Clin Pharmacol"},{"key":"7324_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00228-006-0121-3","volume":"62","author":"A Wennerholm","year":"2006","unstructured":"Wennerholm A, Nordmark A, Pihlsg\u00e5rd M, Mahindi M, Bertilsson L, Gustafsson LL. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. Eur J Clin Pharmacol. 2006;62:539\u201346.","journal-title":"Eur J Clin Pharmacol"},{"key":"7324_CR50","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0887-2333(98)00033-2","volume":"12","author":"F Fontaine","year":"1998","unstructured":"Fontaine F, de Sousa G, Duchene P, Rahmani R. Cytochrome P450 induction and cytotoxic effects of antimalarials in rat hepatocytes. Toxicol In Vitro. 1998;12:545\u20139.","journal-title":"Toxicol In Vitro"},{"key":"7324_CR51","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2174\/138920011795495321","volume":"12","author":"N Pinto","year":"2011","unstructured":"Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab. 2011;12:487\u201397.","journal-title":"Curr Drug Metab"},{"key":"7324_CR52","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/PGPM.S379945","volume":"16","author":"KJ Marwa","year":"2023","unstructured":"Marwa KJ, Kapesa A, Kamugisha E, Swedberg G. The influence of cytochrome P450 polymorphisms on pharmacokinetic profiles and treatment outcomes among malaria patients in sub-Saharan Africa: a systematic review. Pharmacogenomics Person Med. 2023;16:449\u201361.","journal-title":"Pharmacogenomics Person Med"},{"key":"7324_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjid.2024.104400","volume":"28","author":"M Cerilo-Filho","year":"2024","unstructured":"Cerilo-Filho M, Almeida MNG, Sampaio MP, Viagem DJ, Correa RI, Reis NF, et al. Polymorphisms in the cyp-450 gene and malaria: a genotypic and phenotypic relationship with therapeutic failure. Braz J Infect Dis. 2024;28:104400.","journal-title":"Braz J Infect Dis"},{"key":"7324_CR54","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1111\/bcp.14574","volume":"87","author":"AC Almeida","year":"2021","unstructured":"Almeida AC, Elias ABR, Marques MP, de Melo GC, da Costa AG, Figueiredo EFG, et al. Impact of malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients. Br J Clin Pharmacol. 2021;87:1859\u201368.","journal-title":"Br J Clin Pharmacol"},{"key":"7324_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121266","volume":"280","author":"R Li","year":"2022","unstructured":"Li R, Liu J, Ma J, Sun X, Wang Y, Yan J, et al. Fibrinogen improves liver function via promoting cell aggregation and fibronectin assembly in hepatic spheroids. Biomaterials. 2022;280:121266.","journal-title":"Biomaterials"},{"key":"7324_CR56","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/ten.tea.2007.0434","volume":"15","author":"TT Chang","year":"2009","unstructured":"Chang TT, Hughes-Fulford M. Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng Part A. 2009;15:559\u201367.","journal-title":"Tissue Eng Part A"},{"key":"7324_CR57","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41580-022-00531-5","volume":"24","author":"P Kanchanawong","year":"2023","unstructured":"Kanchanawong P, Calderwood DA. Organization, dynamics and mechanoregulation of integrin-mediated cell\u2013ECM adhesions. Nat Rev Mol Cell Biol. 2023;24:142\u201361.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"7324_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajpath.2020.10.011","volume":"191","author":"R Masuzaki","year":"2021","unstructured":"Masuzaki R, Ray KC, Roland J, Zent R, Lee YA, Karp SJ. Integrin \u03b21 establishes liver microstructure and modulates transforming growth factor \u03b2 during liver development and regeneration. Am J Pathol. 2021;191:309\u201319.","journal-title":"Am J Pathol"},{"key":"7324_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034765","volume":"102","author":"H Xie","year":"2023","unstructured":"Xie H, Qin C, Zhou X, Liu J, Yang K, Nong J, et al. Prognostic value and potential molecular mechanism of ITGB superfamily members in hepatocellular carcinoma. Medicine (Baltimore). 2023;102:e34765.","journal-title":"Medicine (Baltimore)"},{"key":"7324_CR60","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S1357-2725(97)00051-4","volume":"29","author":"J-L Guan","year":"1997","unstructured":"Guan J-L. Role of focal adhesion kinase in integrin signaling. Int J Biochem Cell Biol. 1997;29:1085\u201396.","journal-title":"Int J Biochem Cell Biol"},{"key":"7324_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01853-8","volume":"21","author":"SJ Han","year":"2021","unstructured":"Han SJ, Kwon S, Kim KS. Challenges of applying multicellular tumor spheroids in preclinical phase. Cancer Cell Int. 2021;21:152.","journal-title":"Cancer Cell Int"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-026-07324-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-026-07324-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-026-07324-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:02:28Z","timestamp":1777525348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13071-026-07324-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7324"],"URL":"https:\/\/doi.org\/10.1186\/s13071-026-07324-1","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"4 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Co-Author Mr. Adam Aspinall is employed by Medicines for Malaria Venture (MMV).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}